OnDemand Updates on Retina Clinical Trials in 2025 - Featuring 16th P. Kenneth Nase Memorial Lecture


OnDemand Updates on Retina Clinical Trials in 2025 - Featuring 16th P. Kenneth Nase Memorial Lecture Banner



Date & Location
Tuesday, April 8, 2025, 8:00 AM - Wednesday, April 8, 2026, 11:59 PM

Registration
Registration for this activity is free.

Target Audience
Specialties - Retina and Vitreous
Professions - Physician, Student

Credits
AMA PRA Category 1 Credits™ (3.75 hours), Non-Physician Attendance (3.75 hours)

Overview

The 16th P. Kenneth Nase Memorial Lecture was delivered by David S. Boyer, MD of Retina-Vitreous Associates Medical Group in California.

David S. Boyer, M.D. is a Board-certified ophthalmologist specializing in the treatment of diseases of the retina and vitreous. He is Senior Partner at Retina-Vitreous Associates Medical Group with offices in Los Angeles, Beverly Hills, North Hollywood, Torrance, Pasadena, Tarzana, Glendale and La Mirada, California. Dr. Boyer is an Adjunct Clinical Professor of Ophthalmology with the University of Southern California/Keck School of Medicine in Los Angeles, CA. He has an extensive research background and is currently an investigator for various clinical trials. He is one of the leading retinal clinical researchers in the country for new treatments in macular degeneration and diabetic macular edema. A widely-published author and avid lecturer, Dr. Boyer lectures nationally and internationally on retinal research and the innovative approach to the treatment of retinal diseases

Topics covered will include clinical trial design and clinical trial results. Dr. David Boyer will be delivering the Nase Lecture. His lecture will cover clinical trial results for Lumithera for treatment of dry AMD, Ophthea as an adjunct for treatment of wet AMD, and CNTF for treatment of idiopathic perifoveal telangiectasia.

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.


Objectives
At the conclusion of this activity, learners will be able to:

  1. Evaluate the use of Lumithera, a newly FDA-approved treatment for dry AMD.
  2. Understand clinical trial design and the limitations of clinical trials.
  3. Apply results of clinical trials to clinical practice.
  4. Identify patients who are good candidates for clinical trials.
  5. Recognize new and emerging therapies for various retinal diseases.

Accreditation
Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Statement
Wills Eye Hospital designates this Enduring Material for a maximum of 3.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.